Zaaijer Hans L, Vandenbroucke-Grauls C M J E, Franssen E J F
Department of Medical Microbiology and Infection Control, VUMC University Hospital, 1007 MB Amsterdam, The Netherlands.
Ther Drug Monit. 2002 Jun;24(3):444-5. doi: 10.1097/00007691-200206000-00020.
Palivizumab is a humanized, monoclonal antibody used to protect at-risk infants against respiratory syncytial virus (RSV) infection. The regular dosage scheme causes a low initial trough level and accumulation of the antibody after subsequent injections. Using a simple pharmacokinetic model, the authors devised an alternative dosage regimen that might correct these problems while cutting costs by 35%. To spare health care budgets, dosage schemes for future monoclonal antibodies must be chosen carefully.
帕利珠单抗是一种人源化单克隆抗体，用于保护高危婴儿免受呼吸道合胞病毒（RSV）感染。常规给药方案会导致初始谷浓度较低，且后续注射后抗体蓄积。作者使用一个简单的药代动力学模型设计了一种替代给药方案，该方案可能纠正这些问题，同时将成本降低35%。为节省医疗保健预算，必须谨慎选择未来单克隆抗体的给药方案。
